MedTrace Logo

A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

NCT00368069 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2020-07-15

Study results available
· View outcomes & findings →

Summary

This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.

Conditions

Interventions

DRUG

Keppra® extended release formulation - XR

500mg extended release oral tablet, 2 tablets once daily

DRUG

Placebo

oral tablets, 2 tablets once daily

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • Brazil
  • Finland
  • India
  • Mexico
  • Russia
  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00368069 on ClinicalTrials.gov